Unknown

Dataset Information

0

MRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications.


ABSTRACT: mRNA-based drugs have tremendous potential as clinical treatments, however, a major challenge in realizing this drug class will promise to develop methods for safely delivering the bioactive agents with high efficiency and without activating the immune system. With regard to mRNA vaccines, researchers have modified the mRNA structure to enhance its stability and promote systemic tolerance of antigenic presentation in non-inflammatory contexts. Still, delivery of naked modified mRNAs is inefficient and results in low levels of antigen protein production. As such, lipid nanoparticles have been utilized to improve delivery and protect the mRNA cargo from extracellular degradation. This advance was a major milestone in the development of mRNA vaccines and dispelled skepticism about the potential of this technology to yield clinically approved medicines. Following the resounding success of mRNA vaccines for COVID-19, many other mRNA-based drugs have been proposed for the treatment of a variety of diseases. This review begins with a discussion of mRNA modifications and delivery vehicles, as well as the factors that influence administration routes. Then, we summarize the potential applications of mRNA-based drugs and discuss further key points pertaining to preclinical and clinical development of mRNA drugs targeting a wide range of diseases. Finally, we discuss the latest market trends and future applications of mRNA-based drugs.

SUBMITTER: Wang YS 

PROVIDER: S-EPMC10559634 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications.

Wang Yu-Shiuan YS   Kumari Monika M   Chen Guan-Hong GH   Hong Ming-Hsiang MH   Yuan Joyce Pei-Yi JP   Tsai Jui-Ling JL   Wu Han-Chung HC  

Journal of biomedical science 20231007 1


mRNA-based drugs have tremendous potential as clinical treatments, however, a major challenge in realizing this drug class will promise to develop methods for safely delivering the bioactive agents with high efficiency and without activating the immune system. With regard to mRNA vaccines, researchers have modified the mRNA structure to enhance its stability and promote systemic tolerance of antigenic presentation in non-inflammatory contexts. Still, delivery of naked modified mRNAs is inefficie  ...[more]

Similar Datasets

| S-EPMC3202319 | biostudies-other
| S-EPMC9012156 | biostudies-literature
| S-EPMC9726229 | biostudies-literature
| S-EPMC9785933 | biostudies-literature
| S-EPMC10825633 | biostudies-literature
| S-EPMC6632105 | biostudies-literature
| S-EPMC10416113 | biostudies-literature
| S-EPMC7854307 | biostudies-literature
| S-EPMC7200352 | biostudies-literature
| S-EPMC11564657 | biostudies-literature